Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT06055153 Not yet recruiting - Clinical trials for HER-2 Protein Overexpression

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

Start date: September 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, exploratory clinical study.

NCT ID: NCT06039111 Not yet recruiting - Vulvar Cancer Clinical Trials

Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma

IGNITE-V
Start date: October 1, 2023
Phase: Phase 2
Study type: Interventional

The aim of this study is to confirm prospectively if the use of near infrared-indocyanine green (NIR-ICG) alone offers similar accuracy and sensitivity to the gold standard dual technique for sentinel lymph node detection in early stage vulvar cancer.

NCT ID: NCT06016413 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

This study explored the efficacy of adelbelimab (PD-L1 inhibitor) combined with chemotherapy in preoperative induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma

NCT ID: NCT06010212 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Start date: August 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This Study is a Single-center, Single-arm, Phase II Clinical Study. The Primary Objective is to Evaluate the Efficacy and Safety of Fruquintinib, Carrelizumab, Paclitaxel Liposomes combined with Nidaplatin as First-line Treatment in Advanced Esophageal squamous cell carcinoma .

NCT ID: NCT05993858 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC

PC-1
Start date: October 20, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.

NCT ID: NCT05965154 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, one-arm exploratory second-line study of carrilizumab combined with bevacizumab plus capecitabine in relapsed metastatic squamous cell carcinoma of the head and neck.

NCT ID: NCT05962242 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Oropharynx

HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma

HN001
Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and effectiveness of a lower than standard dose of radiation for definitive or adjuvant treatment of head and neck squamous cell carcinomas.

NCT ID: NCT05934929 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of the Oral Cavity

Contribution of Residual Tumour DNA Testing on the Surgical Bed

MARGINS
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.

NCT ID: NCT05929547 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma

Patient Perspectives in Squamous Cell Carcinoma Clinical Trials

Start date: July 2024
Phase:
Study type: Observational

Clinical research participation has historically been heavily biased toward specific demographics. This study will invite several participants to gather a wide range of information on clinical trial experiences for squamous cell carcinoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of squamous cell carcinoma. People with squamous cell carcinoma who are invited to take part in clinical research will benefit from the analysis of the data.

NCT ID: NCT05927844 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Start date: June 2023
Phase: Phase 1
Study type: Interventional

This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.